Cell-free DNA mutational analysis in AITL



Neha Mehta-Shah, MD
Photo by Larry Young
An exploratory study suggests cell-free DNA from peripheral blood may be a viable alternative to tumor DNA for mutational profiling in angioimmunoblastic T-cell lymphoma (AITL). Investigators sequenced cell-free DNA and tumor DNA collected from 13 patients with AITL and found that, in 85% of cases, there was... [Read Article]

Pathogenesis of breast-implant-associated ALCL



Marshall E. Kadin, MD
Photo by Larry Young
A small study suggests an abnormal immune response characterized by the production of interleukin-13 (IL-13) underlies the pathogenesis of breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). The immune response appears to be directed toward bacterial antigens on the surface of the breast implants. Marshall E. Kadin,... [Read Article]

Study sheds light on genetic landscape of HSTL



Sandeep Dave, MD
Photo by Larry Young
Researchers say they have identified new driver genes and oncogenic pathways in hepatosplenic T-cell lymphoma (HSTL). The team found that SETD2, a known tumor suppressor, was the most frequently silenced gene in HSTL. The researchers also found evidence suggesting the JAK-STAT and PI3K pathways could be... [Read Article]

Drug produces high response rates in AITL



DeLarue-Richard-TCLF2017-230.jpg
Richard Delarue, MD
Photo by Larry Young
Treatment with 5-azacitidine (5-AZA) can produce a high response rate in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AITL), according to a small study. The overall response rate (ORR) among AITL patients was 75%, and the complete response (CR) rate was 42%. However, this study also... [Read Article]

OS is worse with refractory vs relapsed PTCL



Lansigan-Fredrick-TCLF2017-230.jpg
Frederick Lansigan, MD
Photo by Larry Young

Patients with refractory peripheral T-cell lymphoma (PTCL) have significantly worse overall survival (OS) than patients with relapsed PTCL, according to data from the COMPLETE registry. The data also showed that patients treated with a curative intent had significantly better OS than patients who received palliative care. However, ... [Read Article]

Regimens seem similarly effective in ENKTL



Huang-Huiqiang-TCLF2017-230.jpg
Huiqiang Huang, MD
Photo by Larry Young

Interim results of a phase 3 trial suggest 2 treatment regimens may provide comparable efficacy in patients with extranodal natural killer/T-cell lymphoma (ENKTL), though 1 regimen appears more toxic than the other. In this ongoing trial, investigators are comparing pegaspargase, gemcitabine, oxaliplatin, and thalidomide (P-Gemox+Thal) to pegaspargase,... [Read Article]

Group proposes new prognostic model for PTCL-NOS



TCLF-2017-session-210.jpg
Session at the 9th Annual
T-cell Lymphoma Forum
Photo by Larry Young

Researchers have used data from the T-Cell Project (TCP) to create a prognostic model for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Analyses have suggested the TCP model is more accurate for PTCL-NOS than 4 other prognostic models—the International Prognostic Index... [Read Article]

Project provides insight into T-cell lymphoma



Federico-Massimo-TCLF2017-230.jpg
Massimo Federico, MD
Photo by Larry Young

The T-Cell Project has provided information that can enhance our understanding of T-cell lymphomas, according to a presentation at the 9th Annual T-cell Lymphoma Forum. The project is a prospective registry that includes data from T-cell lymphoma patients in 15 countries located in 5 different regions of... [Read Article]

Brentuximab vedotin bests standard of care in CTCL



Kim-Youn-TCLF2017-230.jpg
Youn Kim, MD
Photo by Larry Young

The phase 3 ALCANZA trial is the first to convincingly demonstrate that a new systemic agent can be more effective than standard of care (SOC) options for cutaneous T-cell lymphoma (CTCL), according to a speaker at the 9th Annual T-cell Lymphoma Forum. The trial showed significant improvements... [Read Article]